December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

9.445 -0.265 (-2.73%)
Streaming Delayed Price Updated: 3:54 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zevra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On? ↗
Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results. 
Via Benzinga
News headline image
Zevra Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
News headline image
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock ↗
 
Via Benzinga
News headline image
Zevra Therapeutics Mixed Q2 Results: Details ↗
Zevra Therapeutics reported its second-quarter financial results Tuesday. Here's a look at the details. 
Via Benzinga
News headline image
Zevra Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease ↗
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
Via Benzinga
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗
ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
PubMatic, Eventbrite, Five9 And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases ↗
FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Insiders Buying Zevra Therapeutics And 1 Other Stock ↗
 
Via Benzinga
News headline image
Insiders Buying Barnes & Noble Education And 2 Other Stocks ↗
 
Via Benzinga
SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
Via AB Newswire
News headline image
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base ↗
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
Via Benzinga
News headline image
ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
ZVRA stock results show that Zevra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value
Via Investor Brand Network
News headline image
ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023 ↗
ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For March 28, 2024 ↗
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.